June Sanson is a senior level patient advocate with over 20 years of experience in the biotech and pharmaceutical industry. She has held many leadership roles in marketing, lifecycle strategy, and patient advocacy. She has expertise in rare diseases, neurology, and psychiatry. Her emphasis is patient engagement, quality of care, education, research, and improving outcomes for people living with CNS related conditions. June studied Psychology at the University of California, Berkeley and lives in San Diego, California.
Rüdiger is a scientist by training with a Ph.D. in pharmacology who has been working in the pharmaceutical industry for 25 years. He held various roles in Sales and Marketing before serving as Business Unit Director in Germany for large pharmaceutical corporations (J&J, BMS). He worked as General Manager for Germany and Central / Eastern Europe for Shire (today part of Takeda) before founding the first foreign affiliate for Ultragenyx, a company exclusively focused on Rare Diseases with a high unmet medical need, as General Manager in 2016. Rüdiger has launched multiple Orphan Drugs in Germany, Poland, and other CEE countries, represented his company in national and international industry associations working groups on Orphan Drugs and has ample experience in pricing and commercializing Orphan Drugs in different health care systems.
Dairine is a pharmaceutical industry executive with 20 years experience in the pharmaceutical, biologic and device industries, including 9 years in senior management positions in the Irish Health Products Regulatory Authority (HPRA) working with both the European Medicines Agency (EMA) and the European Commission. She led the establishment of the National Health Regulatory Agency for Pharmaceutical Products in Bahrain and has been involved in the successful global clinical development and post-marketing management of many pharmaceutical products across multiple therapeutic areas, many for rare diseases. She was global Vice President, Strategic Regulatory Affairs at ICON for 2 years before co-founding and successfully leading the start-up phase of Open Orphan Plc, an Irish CRO for orphan drugs.
She is currently a NED for Soleno Therapeutics Europe Ltd., Omnispirant Ltd. and Reneurx Ltd. and serves on the board of Fighting Blindness as well as providing strategic support to pharma companies focussed on development of a novel therapies for rare diseases.
Dairine is a pharmacist and holds a PhD in pharmacy and a certificate in international business.
June Sanson is a senior level patient advocate with over 20 years of experience in the biotech and pharmaceutical industry. She has held many leadership roles in marketing, lifecycle strategy, and patient advocacy. She has expertise in rare diseases, neurology, and psychiatry. Her emphasis is patient engagement, quality of care, education, research, and improving outcomes for people living with CNS related conditions. June studied Psychology at the University of California, Berkeley and lives in San Diego, California.
Rüdiger is a scientist by training with a Ph.D. in pharmacology who has been working in the pharmaceutical industry for 25 years. He held various roles in Sales and Marketing before serving as Business Unit Director in Germany for large pharmaceutical corporations (J&J, BMS). He worked as General Manager for Germany and Central / Eastern Europe for Shire (today part of Takeda) before founding the first foreign affiliate for Ultragenyx, a company exclusively focused on Rare Diseases with a high unmet medical need, as General Manager in 2016. Rüdiger has launched multiple Orphan Drugs in Germany, Poland, and other CEE countries, represented his company in national and international industry associations working groups on Orphan Drugs and has ample experience in pricing and commercializing Orphan Drugs in different health care systems.
Dairine is a pharmaceutical industry executive with 20 years experience in the pharmaceutical, biologic and device industries, including 9 years in senior management positions in the Irish Health Products Regulatory Authority (HPRA) working with both the European Medicines Agency (EMA) and the European Commission. She led the establishment of the National Health Regulatory Agency for Pharmaceutical Products in Bahrain and has been involved in the successful global clinical development and post-marketing management of many pharmaceutical products across multiple therapeutic areas, many for rare diseases. She was global Vice President, Strategic Regulatory Affairs at ICON for 2 years before co-founding and successfully leading the start-up phase of Open Orphan Plc, an Irish CRO for orphan drugs.
She is currently a NED for Soleno Therapeutics Europe Ltd., Omnispirant Ltd. and Reneurx Ltd. and serves on the board of Fighting Blindness as well as providing strategic support to pharma companies focussed on development of a novel therapies for rare diseases.
Dairine is a pharmacist and holds a PhD in pharmacy and a certificate in international business.
Mariusz Olejniczak is a Graduate of Biotechnology at the University of Life Sciences in Poznań. Experienced professional in medicinal products, medical devices, supplements and plant protection products R&D at every stage - from planning and scientific advice through supervision to the closure and finalization of the project. He is a founder of several start-ups in the e-health industry and a member of the board and supervisory board of several R&D companies. Mariusz is the author of the publication "Change of the product development model as an opportunity for the Polish pharmaceutical industry” (in Polish). Member of the editorial committee of the book "Clinical Trials” (in Polish). Lecturer in postgraduate study programs.
.jpg)
Andreas Uttenweiler is currently heading the Patient Value Access & Public Affairs Department and member of the leadership team of Takeda Switzerland. He’s a biochemist and holds both a PhD in cell biology and a MBA in General Management. Previously, he has held regulatory, commercial, market access and public affairs positions at Cilag, Novartis, Baxter, Baxalta and Shire. He’s an expert in the field of Orphan Drugs and (board) member of several external associations.
Dr. Agarwal is an Assistant Professor of Surgery at Harvard Medical School and a plastic surgeon at the Brigham and Women’s Hospital. He leads a basic science laboratory developing innovative cell therapies for rare diseases. His laboratory has previously enjoyed funding from the Million Dollar Bike Ride Foundation, and currently holds funding from the International FOP Association and Harvard Stem Cell Institute to study modified stem cell transplants to treat FOP, a rare genetic condition causing ectopic bone formation. In addition, Dr. Agarwal holds IP for drug treatment of FOP.
Dr. Agarwal also serves as a founder and Partner of Mainspring Venture Partners, a Boston-based boutique venture capital firm targeting innovative therapeutics and diagnostics for investment. The firm is committed to supporting innovative cell and gene therapies which are thoughtfully designed to address clinical, unmet need.
Dr Subir Roy is a trained physician with dual post graduate specialization in diabetes and clinical research. He also holds a full time MBA degree from Indian School of Business with specializations in marketing and healthcare.
He has ~15 years of experience in the pharmaceutical industry, in both medical affairs and commercial roles. Dr Subir currently works as Associate Director for Global Medical Affairs at Takeda Pharmaceuticals in Boston.
At Takeda he has been instrumental in initiating several innovative projects aimed at transforming patient lives. Recently his project on use of AI for diagnosis of Fabry Disease got picked by MIT and he is currently supporting MIT as Principal Investigator for that project.
Dr Roy is known for his passion for science. During his free time, he writes extensively on his website www.wisethalamus.com that aims at investigating challenging medical questions.
.jpg)
Dr Davy Yeung’s career to date encompasses academia and the NHS. He has made valuable contributions to clinical research at the University of Cambridge, Imperial College and other major academic institutions.
Dr Yeung was also the Head of Research at various UK Hospital Trusts. During his time in the NHS, he gained considerable insight into the governance and delivery of clinical research in the UK. This unique perspective enables our sponsors to select, initiate and manage UK investigative sites for their clinical studies rapidly and effectively.
Having collaborated with a wide range of influential leaders in the field of clinical research, Dr Yeung is himself highly respected and well known in the UK’s healthcare research and development sector.
